A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
Best practices for grounding brand decision-making in insights
In today’s evolving pharmaceutical landscape, harnessing the power of insights is more critical than ever. Integrating primary, secondary, and analytical...